CJC-1295 / Ipamorelin
CJC-1295/Ipamorelin is one of the most widely researched growth hormone-stimulating peptide combinations. CJC-1295 extends the natural GHRH signal while Ipamorelin selectively triggers GH release from the pituitary — together creating a synergistic, physiological pulse that mirrors the body's own GH secretion pattern.
Research Highlights
Growth Hormone Stimulation
CJC-1295 is a GHRH analog that extends the half-life of endogenous GHRH, while Ipamorelin is a selective GHS-R agonist. Together they create a powerful, synergistic pulse of growth hormone release from the pituitary gland.
Sleep & Recovery
Growth hormone is predominantly released during deep sleep. Research on CJC-1295/Ipamorelin explores how amplifying this natural nocturnal GH pulse may enhance sleep quality, cellular repair, and overnight recovery.
Body Composition Research
Elevated GH levels are associated with increased lean muscle mass and reduced adipose tissue. Research studies this combination for its potential role in body composition optimization and metabolic rate enhancement.
Physiological GH Release
Unlike direct GH administration, this combination stimulates the pituitary to release GH in a natural, pulsatile pattern. Research suggests this approach preserves the feedback loop and avoids the desensitization seen with continuous GH exposure.
Why This Combination Works
Think of it like a two-key system. CJC-1295 is a modified version of Growth Hormone-Releasing Hormone (GHRH). Its Drug Affinity Complex (DAC) modification allows it to bind to albumin in the blood, extending its half-life from minutes to nearly a week. This keeps the GHRH signal active and primes the pituitary.
Ipamorelin is a selective ghrelin receptor agonist (GHS-R agonist). When it binds to the pituitary, it triggers a clean, selective pulse of GH release — without significantly raising cortisol or prolactin, which is a key advantage over older GH secretagogues like GHRP-2 or GHRP-6.
Together, they work on two separate receptor systems simultaneously. CJC-1295 amplifies the baseline GHRH signal while Ipamorelin triggers the acute GH pulse. Research shows this dual-pathway approach produces significantly greater GH release than either peptide alone, while maintaining the natural pulsatile pattern that the body's feedback systems recognize.
Technical Data
Research Use Only
All products are intended for laboratory and research purposes only. Not for human consumption, veterinary use, or clinical application. For use by qualified researchers in controlled settings only. These statements have not been evaluated by the FDA.